

#	ARTICLE	IF	CITATIONS
1	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
2	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	7.1	33
3	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	4.1	10
4	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. <i>American Heart Journal</i> , 2022, 246, 136-143.	2.7	8
5	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. <i>Advances in Therapy</i> , 2022, 39, 1832-1843.	2.9	1
6	Endovascular therapeutic hypothermia adjunctive to percutaneous coronary intervention in acute myocardial infarction: realistic simulation as a game changer. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 0104.	1.4	0
7	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	2.7	4
8	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
9	Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial. <i>Therapeutic Hypothermia and Temperature Management</i> , 2021, 11, 135-144.	0.9	9
10	Covid-19 Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning. <i>Analytical Chemistry</i> , 2021, 93, 2471-2479.	6.5	66
11	Associaçãõ entre Terapia com Estatinas e Menor Incidênci de Hiperglicemia em Pacientes Internados com SÃndromes Coronarianas Agudas. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 285-294.	0.8	1
12	Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , 2021, 8, e001499.	2.3	18
13	Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1277-1286.	2.8	10
14	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPA-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	7.1	33
15	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	7.1	70
16	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	4.1	75
17	Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19. <i>Life Science Alliance</i> , 2021, 4, e202000946.	2.8	25
18	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. <i>Advances in Therapy</i> , 2021, 38, 3911-3923.	2.9	22

#	ARTICLE	IF	CITATIONS
19	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	6.1	12
20	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.8	45
21	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	27.0	778
22	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	1.7	6
23	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	27.0	712
24	Posicionamento sobre Hipertensão Arterial e Espiritualidade – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 599-613.	0.8	0
25	Factors associated with actively working in the very long-term following acute coronary syndrome. <i>Clinics</i> , 2021, 76, e2553.	1.5	0
26	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.2	71
27	HDL proteome remodeling associates with COVID-19 severity. <i>Journal of Clinical Lipidology</i> , 2021, 15, 796-804.	1.5	22
28	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <i>Journal of Cardiology</i> , 2021, , .	1.9	2
29	Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. <i>Open Heart</i> , 2021, 8, e001726.	2.3	5
30	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Outcomes, 2020, 6, 284-292.	4.0	10
31	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 167-175.	3.0	12
32	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	1.8	18
33	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020, 41, 1625-1632.	2.2	27
34	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	1.6	145
35	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
36	Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. <i>Advances in Therapy</i> , 2020, 37, 420-430.	2.9	6

#	ARTICLE	IF	CITATIONS
37	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	13.7	425
38	Relation of High LipoproteinÂ(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020, 37, 4568-4584.	2.9	8
39	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
40	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020, 17, 491-500.	1.6	56
41	Diabetes association with selfâ€reported health, resource utilization, and prognosis postâ€myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	1.8	3
42	Sonothrombolysis Improves Myocardial Dynamics and Microvascular Obstruction Preventing Left Ventricular Remodeling in Patients With ST Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009536.	2.6	12
43	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015785.	3.7	7
44	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	10.9	8
45	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.4	340
46	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	1.7	9
47	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2020, 75, 289-300.	2.8	29
48	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019, 7, 618-628.	11.4	207
49	Lipid transfer to highâ€density lipoproteins in coronary artery disease patients with and without previous cerebrovascular ischemic events. <i>Clinical Cardiology</i> , 2019, 42, 1100-1105.	1.8	7
50	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180.	13.7	155
51	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	27.0	255
52	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
53	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
54	Sonothrombolysis in ST-Segment Elevation Myocardial Infarction TreatedÂWith Primary PercutaneousÂCoronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2832-2842.	2.8	63

#	ARTICLE	IF	CITATIONS
55	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	2.8	64
56	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
57	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	27.0	833
58	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
59	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 217-224.	2.1	6
60	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , 2019, 291, 36-41.	1.7	3
61	Urgent Revascularization Strategies in Patients With Diabetes Mellitus and Acute Coronary Syndrome. <i>Canadian Journal of Cardiology</i> , 2019, 35, 993-1001.	1.7	11
62	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	1.8	24
63	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.1	42
64	Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2019, 30, 152-155.	0.7	0
65	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	27.0	4,159
66	Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events. <i>Clinics</i> , 2019, 74, e1222.	1.5	2
67	Cardiology Training in Brazil and Developed Countries: Some Ideas for Improvement. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 768-774.	0.8	2
68	High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-ST Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 357-363.	0.8	2
69	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	2.7	13
70	Stem cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. <i>Clinical Cardiology</i> , 2018, 41, 392-399.	1.8	32
71	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. <i>Circulation</i> , 2018, 137, 771-780.	1.6	34
72	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582.	1.6	304

#	ARTICLE	IF	CITATIONS
73	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2392-2401.	2.8	236
74	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	6.1	65
75	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	13.7	426
76	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	13.7	651
77	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 319-328.	13.7	628
78	Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop. <i>Clinics</i> , 2018, 73, e515s.	1.5	1
79	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	27.0	2,211
80	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	3.7	8
81	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 2269-2279.	13.7	70
82	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475.	2.8	10
83	Predictors of subclinical carotid atherosclerosis in middle-aged women. <i>PLoS ONE</i> , 2018, 13, e0197582.	2.5	10
84	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 435-442.	2.6	7
85	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	3.9	7
86	Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1013-1019.	1.8	1
87	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. <i>Circulation</i> , 2017, 135, 1136-1144.	1.6	21
88	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017, 236, 54-60.	1.7	27
89	Myocardial Inactivation of Thyroid Hormones in Patients with Aortic Stenosis. <i>Thyroid</i> , 2017, 27, 738-745.	4.5	9
90	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	27.0	593

#	ARTICLE	IF	CITATIONS
91	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	27.0	4,179
92	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
93	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017, 389, 1799-1808.	13.7	174
94	Sympathetic nervous activity in patients with acute coronary syndrome: a comparative study of inflammatory biomarkers. <i>Clinical Science</i> , 2017, 131, 883-895.	4.3	12
95	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 ^Â P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	3.2	19
96	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
97	Methotrexate carried in lipid core nanoparticles reduced the infarction size and improved left ventricle function following acute myocardium infarction induced in rats. <i>Atherosclerosis</i> , 2017, 263, e126.	0.8	0
98	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1833-1842.	13.7	948
99	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	27.0	6,227
100	Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017, 40, 1197-1204.	1.8	12
101	Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 3767-3784.	6.7	24
102	Neurovascular control during exercise in acute coronary syndrome patients with Gln27Glu polymorphism of β 2-adrenergic receptor. <i>PLoS ONE</i> , 2017, 12, e0173061.	2.5	2
103	Pregnancy in Woman with Kawasaki Disease and Multiple Coronary Artery Aneurysms. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 110, 97-100.	0.8	4
104	Diagnostic Ultrasound Impulses Improve Microvascular Flow in Patients With STEMI Receiving Intravenous Microbubbles. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2506-2515.	2.8	68
105	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	2.8	303
106	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	2.8	66
107	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	53
108	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	2.0	83

#	ARTICLE	IF	CITATIONS
109	Preprocedural statin therapy, inflammation, and myocardial injury in low-risk stable coronary artery disease patients submitted to coronary stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 222-229.	1.7	7
110	Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 275-284.	2.2	18
111	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
112	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1187-1193.	1.7	7
113	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	2.8	15
114	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 696-705.	8.6	141
115	SBC Guidelines on Unstable Angina and Non-ST-Elevation Myocardial Infarction: Executive Summary. <i>Arquivos Brasileiros De Cardiologia</i> , 2015, 105, 214-27.	0.8	7
116	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	27.0	3,337
117	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. <i>Journal of the American Heart Association</i> , 2015, 4, e001505.	3.7	62
118	Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. <i>Heart</i> , 2015, 101, 119-125.	2.9	15
119	Influence of proven oral therapies in the very old with acute coronary syndromes: A 15year experience. <i>International Journal of Cardiology</i> , 2015, 198, 213-215.	1.7	1
120	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	27.0	1,585
121	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> . 2015. 170. 683-694.e3.	2.7	26
122	Giant and Calcified Post-Infarction True Left Ventricular Aneurysm: What to Do?. <i>Arquivos Brasileiros De Cardiologia</i> , 2015, 106, 259-62.	0.8	0
123	Do Diabetic Patients with Acute Coronary Syndromes Have a Higher Threshold for Ischemic Pain?. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 183-91.	0.8	1
124	Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <sc>TIMI</sc> 38 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014, 37, 293-299.	1.8	5
125	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	7.4	375
126	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467

#	ARTICLE	IF	CITATIONS
127	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	2.2	70
128	Accuracy of multidetector computed tomography for detection of coronary artery stenosis in acute coronary syndrome compared with stable coronary disease: A CORE64 multicenter trial substudy. <i>International Journal of Cardiology</i> , 2014, 177, 385-391.	1.7	14
129	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
130	Extent of Coronary and Myocardial Disease and Benefit From Surgical Revascularization in LV Dysfunction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 553-561.	2.8	92
131	Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. <i>International Journal of Cardiology</i> , 2014, 176, 1170-1172.	1.7	4
132	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	2.8	47
133	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	2.8	40
134	Cardiovascular clinical research in South America. <i>American Heart Journal</i> , 2013, 165, 848-853.	2.7	2
135	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
136	Anticoagulation With Otamixaban and Ischemic Events in Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1145.	7.4	58
137	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. <i>Lancet, The</i> , 2013, 382, 605-613.	13.7	105
138	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. <i>Circulation</i> , 2013, 127, 673-680.	1.6	72
139	Abnormal muscle vascular responses during exercise in myocardial infarction patients. <i>International Journal of Cardiology</i> , 2013, 165, 210-212.	1.7	2
140	Características clínicas, angiográficas e evoluções a longo prazo em pacientes com arterite de Takayasu e síndrome coronária aguda. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 297-302.	0.5	11
141	Late percutaneous coronary intervention for an occluded infarct-related artery in patients with preserved infarct zone viability: A pooled analysis of cardiovascular magnetic resonance studies. <i>Cardiology Journal</i> , 2013, 20, 552-559.	1.2	5
142	The Bleeding Risk Score as a Mortality Predictor in Patients with Acute Coronary Syndrome. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 511-8.	0.8	6
143	Unrecognized Diabetes and Myocardial Necrosis: Predictors of Hyperglycemia in Myocardial Infarction. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, , .	0.8	5
144	Unrecognized diabetes and myocardial necrosis: predictors of hyperglycemia in myocardial infarction. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 100, 404-11.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
146	In Patients With Acute Myocardial Infarction, the Impact of Hyperglycemia as a Risk Factor for Mortality Is Not Homogeneous Across Age-Groups. <i>Diabetes Care</i> , 2012, 35, 150-152.	8.6	11
147	Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity. <i>Clinics</i> , 2012, 67, 1117-1121.	1.5	2
148	Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2012, 23, 118-125.	0.7	5
149	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
150	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO". <i>Circulation</i> , 2012, 126, .	1.6	1
151	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	1.6	176
152	Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. <i>International Journal of Cardiology</i> , 2012, 158, 400-404.	1.7	42
153	Utilizaç�o de terap�uticas comprovadamente eficazes no tratamento da coronariopatia aguda: comparaç�o entre diferentes regi�es brasileiras. An�lise do Registro Brasileiro de S�ndromes Coronarianas Agudas (BRACE - Brazilian Registry on Acute Coronary Syndromes). <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 98, 282-289.	0.8	37
154	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2012, 125, 2914-2921.	1.6	112
155	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	27.0	841
156	US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 230-238.	2.1	10
157	Management of acute coronary syndrome in South Africa : insights from the ACCESS (Acute Coronary) Tj ETQq1 1 0.784314 rgBT /Ov <i>Cardiovascular Journal of Africa</i> , 2012, 23, 365-370.	0.4	54
158	Brazilian contribution to a better understanding of geriatric cardiology. <i>Journal of Geriatric Cardiology</i> , 2012, 9, 77-77.	0.2	0
159	Oclus�o de comunicaç�o interventricular p�s-infarto com pr�tese percut�nea CERA. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 99, e112-e113.	0.8	0
160	Aplicaç�o de hipotermia terap�utica em paciente com coronariopatia aguda. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 99, e122-e124.	0.8	0
161	1st Guidelines of the Brazilian Society of Cardiology on processes and skills for education in cardiology in Brazil--executive summary. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 98, 98-103.	0.8	3
162	Effects of Long-Term Exercise Training on Autonomic Control in Myocardial Infarction Patients. <i>Hypertension</i> , 2011, 58, 1049-1056.	2.7	87

#	ARTICLE	IF	CITATIONS
163	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 57, 672-684.	2.8	457
164	Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. <i>New England Journal of Medicine</i> , 2011, 364, 1617-1625.	27.0	734
165	Skeletonized coronary arteries: pathophysiological and clinical aspects of vascular calcification. <i>Vascular Health and Risk Management</i> , 2011, 7, 143.	2.3	13
166	CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. <i>BMC Medical Genetics</i> , 2011, 12, 13.	2.1	73
167	Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery†. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2011, 12, 778-783.	1.1	12
168	Aos pacientes com coronariopatia aguda, apenas a dosagem inicial de troponina é o melhor que temos a oferecer?. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 432-433.	0.8	1
169	Reduced expression of systemic proinflammatory and myocardial biomarkers after off-pump versus on-pump coronary artery bypass surgery: A prospective randomized study. <i>Journal of Critical Care</i> , 2010, 25, 305-312.	2.2	50
170	Ausência de interação do clopidogrel-estatina em pacientes submetidos a implante de "stent" coronário. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 95, 321-327.	0.8	4
171	Obesidade e doença arterial coronariana: papel da inflamação vascular. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 94, 273-279.	0.8	57
172	Effect of ß-Blockers on the Risk of Atrial Fibrillation in Patients with Acute Myocardial Infarction. <i>Clinics</i> , 2010, 65, 265-270.	1.5	13
173	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATO inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010, 31, 3006-3016.	2.2	389
174	The Role of Invasive Therapies in Elderly Patients with Acute Myocardial Infarction. <i>Clinics</i> , 2009, 64, 553-560.	1.5	9
175	Prevalência de Chlamydia Pneumoniae e Mycoplasma Pneumoniae em diferentes formas da doença coronariana. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 92, 439-445.	0.8	13
176	Influência de leucócitos e glicemia no prognóstico de pacientes com infarto agudo do miocárdio. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 92, 88-93.	0.8	12
177	Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2009, 119, 2758-2764.	1.6	155
178	Native LDL-Cholesterol Mediated Monocyte Adhesion Molecule Overexpression is Blocked by Simvastatin. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 215-220.	2.6	14
179	Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 106-116.	2.1	2
180	Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens. <i>Drugs</i> , 2009, 69, 1433-1443.	10.9	8

#	ARTICLE	IF	CITATIONS
181	Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes. <i>Atherosclerosis</i> , 2009, 204, 165-170.	0.8	22
182	Differences Among Low-Molecular-Weight Heparins: Evidence in Patients With Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 440-445.	1.9	14
183	Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction " MiHeart/AMI study. <i>Trials</i> , 2008, 9, 41.	1.6	12
184	Differences in the Inflammatory Response between Patients with and Those without Diabetes Mellitus after Coronary Stenting. <i>Journal of Interventional Cardiology</i> , 2008, 21, 403-409.	1.2	14
185	Comparison of MB Fraction of Creatine Kinase Mass and Troponin I Serum Levels With Necropsy Findings in Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 311-314.	1.6	27
186	Invasive therapies after fibrinolysis. <i>International Journal of Cardiology</i> , 2008, 127, 436.	1.7	0
187	Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. <i>Annals of Thoracic Surgery</i> , 2008, 85, 1261-1270.	1.3	260
188	Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease" A randomized placebo-controlled study. <i>Atherosclerosis</i> , 2008, 196, 434-442.	0.8	82
189	Depression: a predictor of smoking relapse in a 6-month follow-up after hospitalization for acute coronary syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 89-94.	2.8	54
190	History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure. <i>Hypertension</i> , 2008, 52, 271-278.	2.7	22
191	Cardiomiopatia de takotsubo como causa de disfunÃ§Ã£o ventricular transitÃ³ria. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 90, e17-e20.	0.8	1
192	A influÃªncia do plano de saÃºde na evoluÃ§Ã£o a longo prazo de pacientes com infarto agudo do miocÃ¡rdio. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 91, 347-51.	0.8	3
193	Left Ventricular Free-Wall Rupture After Acute Myocardial Infarction Imaged by Cardiovascular Magnetic Resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2007, 9, 719-721.	3.3	9
194	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , 2007, 28, 2070-2076.	2.2	7
195	Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. <i>European Heart Journal</i> , 2007, 28, 1566-1573.	2.2	56
196	Smoking-associated factors in myocardial infarction and unstable angina: Do gender differences exist?. <i>Addictive Behaviors</i> , 2007, 32, 1295-1301.	3.0	4
197	Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. <i>American Heart Journal</i> , 2007, 154, 54-61.	2.7	19
198	A comparison of percutaneous coronary intervention and surgical revascularization after fibrinolysis for acute myocardial infarction. Insights from the InTIME-2 trial. <i>International Journal of Cardiology</i> , 2007, 116, 383-388.	1.7	5

#	ARTICLE	IF	CITATIONS
199	Enhanced inflammatory response following coronary stent implantation in stable angina patients. <i>International Journal of Cardiology</i> , 2007, 118, 69-75.	1.7	4
200	Determination of Size and Transmural Extent of Acute Myocardial Infarction by Real-time Myocardial Perfusion Echocardiography: A Comparison with Magnetic Resonance Imaging. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 126-135.	2.8	13
201	Baseline glucose and left ventricular remodeling after acute myocardial infarction. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 294-299.	2.3	15
202	MULTIPLE ARTERY ANEURYSMS FOUND DURING ACUTE CORONARY SYNDROME INVESTIGATION. AN UNREPORTED ASSOCIATION. <i>Clinics</i> , 2007, 62, 635-636.	1.5	1
203	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	27.0	1,104
204	Regression of coronary artery outward remodeling in patients with non- σ ST-segment acute coronary syndromes: A longitudinal study using noninvasive magnetic resonance imaging. <i>American Heart Journal</i> , 2006, 152, 1123-1132.	2.7	13
205	Ativa σ plaquet σ ria em formas cl σ nicas distintas da doen σ a arterial coronariana (papel da P-selectina) Tj ETQq1 1 0.784314 rgB 446-450.	0.8	12
206	Vasoespasm coronariano induzido pela ecocardiografia sob estresse pela dobutamina-atropina. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, e250-e253.	0.8	11
207	Glucose, insulin, and acute myocardial infarction: reply. <i>European Heart Journal</i> , 2006, 27, 2142-2143.	2.2	0
208	Prognostic significance of the change in glucose level in the first 24h after acute myocardial infarction: results from the CARDINAL study. <i>European Heart Journal</i> , 2006, 27, 1289-1297.	2.2	161
209	Cirurgia de revasculariza σ o na fase aguda do infarto do mioc σ rdio: an σ lise dos fatores pr σ -operat σ rios preditores de mortalidade. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, 254-259.	0.8	4
210	Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. <i>European Heart Journal</i> , 2005, 26, 36-43.	2.2	48
211	Detection of Functional Recovery Using Low-Dose Dobutamine and Myocardial Contrast Echocardiography After Acute Myocardial Infarction Treated with Successful Thrombolytic Therapy. <i>Echocardiography</i> , 2005, 22, 496-502.	0.9	13
212	Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). <i>American Journal of Cardiology</i> , 2005, 95, 614-618.	1.6	32
213	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. <i>European Heart Journal</i> , 2005, 26, 1964-1970.	2.2	120
214	Platelet and leukocyte adhesion and activation in unstable angina and post-PTCA. <i>International Journal of Cardiology</i> , 2005, 99, 423-428.	1.7	15
215	Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 425-431.	2.8	350
216	Value of myocardial contrast echocardiography for predicting left ventricular remodeling and segmental functional recovery after anterior wall acute myocardial infarction. <i>Journal of the American Society of Echocardiography</i> , 2004, 17, 923-932.	2.8	28

#	ARTICLE	IF	CITATIONS
217	The role of gender in the long-term prognosis of patients with myocardial infarction submitted to fibrinolytic treatment. <i>Annals of Epidemiology</i> , 2004, 14, 17-23.	1.9	19
218	Angiographic aspects of ruptured plaque in patients with acute myocardial infarction: correlation with clinical and laboratory variables. <i>Atherosclerosis</i> , 2004, 175, 125-130.	0.8	2
219	Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2004, 177, 161-166.	0.8	170
220	Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 129-132.	2.6	8
221	ST-segment resolution and late (6-month) left ventricular remodeling after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 451-453.	1.6	17
222	Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. <i>American Heart Journal</i> , 2003, 145, 1101.	2.7	7
223	Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Circulation</i> , 2003, 108, 1184-1190.	1.6	315
224	Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction. <i>Circulation</i> , 2003, 108, 1176-1183.	1.6	176
225	Primary coronary angioplasty in a nonagenarian. <i>Arquivos Brasileiros De Cardiologia</i> , 2002, 78, 114-21.	0.8	2
226	Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. <i>Lancet, The</i> , 2001, 358, 605-613.	18.7	724
227	Prognosis of acute myocardial infarction in the thrombolytic era: medical evaluation is still valuable. <i>European Journal of Heart Failure</i> , 2001, 3, 569-576.	7.1	12
228	Fatores prognósticos da revascularização na fase aguda do infarto agudo do miocárdio. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2001, 16, 195.	0.6	6
229	Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2001, 22, 2104-2115.	2.2	21
230	How can adherence to guidelines be improved? The case of fibrinolytics. <i>Sao Paulo Medical Journal</i> , 2001, 119, 192-192.	0.9	1
231	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. <i>Arquivos Brasileiros De Cardiologia</i> , 2000, 75, 296-302.	0.8	3
232	Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. <i>European Heart Journal</i> , 2000, 21, 2005-2013.	2.2	154
233	Effect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms. <i>Heart</i> , 1999, 82, 689-693.	2.9	15
234	Early infarct artery collateral flow does not improve long-term survival following thrombolytic therapy for acute myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 83, 21-26.	1.6	44

#	ARTICLE	IF	CITATIONS
235	Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin) Tj ETQq1 1 0.784314 rgBT /Overload (enalapril or lisinopril). American Journal of Cardiology, 1999, 83, 1497-1499.	1.6	132
236	Sinus bradycardia as a predictor of right coronary artery occlusion in patients with inferior myocardial infarction. International Journal of Cardiology, 1999, 68, 75-82.	1.7	20
237	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. Journal of the American College of Cardiology, 1999, 33, 1879-1885.	2.8	119
238	The role of antegrade and collateral flow in relation to left ventricular function post-thrombolysis. International Journal of Cardiology, 1997, 61, 47-54.	1.7	6
239	Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase. American Journal of Cardiology, 1996, 78, 1049-1052.	1.6	13
240	Echocardiographic Features of Ventricular Septal Rupture with Right Ventricular Aneurysm After Acute Myocardial Infarction. Echocardiography, 1996, 13, 303-308.	0.9	5
241	Electrocardiography in Chagas' heart disease. Sao Paulo Medical Journal, 1995, 113, 802-813.	0.9	36
242	Surgical revascularization after fibrinolysis in acute myocardial infarction. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 1454-1459.	0.8	7
243	Pheochromocytoma with Echocardiographic Features of Obstructive Hypertrophic Cardiomyopathy. Angiology, 1994, 45, 985-989.	1.8	16
244	Valvular Surgery During Infective Endocarditis. Vascular Surgery, 1994, 28, 341-348.	0.3	0
245	Acute myocardial infarction treated with intravenous streptokinase: 6-year follow-up. International Journal of Cardiology, 1993, 38, 253-262.	1.7	5
246	Diagnostic Features, Surgical Treatment, and Postoperative Follow-up of the Aortic-Left Ventricular Tunnel. Vascular Surgery, 1993, 27, 99-104.	0.3	0
247	Severe Mitral Regurgitation Due to Uncommon Cystic Form of Fibroelastoma—A Case Report. Vascular Surgery, 1993, 27, 74-77.	0.3	0
248	Clinical and laboratory signs of reperfusion: are they reliable?. International Journal of Cardiology, 1989, 25, 313-320.	1.7	25